Over the last decade, an increasing number of drug development sponsors have conducted endometriosis clinical trials to explore more specific therapeutic targeting approaches for this chronic disease. While these changes are promising to address ongoing unmet medical needs, clinical trials continue to face many hurdles due to challenges with diagnosing patients, navigating restrictive regulatory guidelines and designing appropriate trials.
Register for this educational webinar, which will cover several aspects of endometriosis drug development through the perspectives of three specialists. From the translational research gaps to current clinical trial practices, trial design and enrollment, participants will gain a greater understanding of both the medical and operational considerations for supporting these trials, as well as insights on the patient journey in the industry’s quest to create safer and more efficacious treatments.
Friedrich Wieser, MD, Medical Director, Labcorp Drug Development
Dr. Wieser is a trained gynecologist with a fellowship in reproductive medicine and over 20 years of clinical research experience in Women’s Health in academia and pharmaceutical industry settings. Dr. Wieser accomplished the highest academic qualification for studies in endometriosis at the Medical University of Vienna. He has led NIH-funded investigations on endometriosis and conducted studies on menopause, infertility, and gynecologic medical devices. He held a leadership role in Women’s Health at Merck KGaA Healthcare, leading drug development and early stage innovation in the field of Human Reproduction prior joining Labcorp in the Women’s Health group.
Hugh Taylor, MD, Professor of Women’s Health and chair of the Department of Obstetrics, Gynecology and Reproductive Science, Yale School of Medicine
Dr. Taylor is a board-certified specialist in obstetrics/gynecology and in reproductive endocrinology. He has been a principal investigator on 15 NIH grants, and site PI or co-investigator on numerous additional NIH-funded projects. His clinical research centers on implantation, endometriosis and menopause. Dr. Taylor is also a professor of molecular, cellular and developmental biology at Yale University, where his basic science research focuses on uterine development and the regulation of developmental gene expression by sex steroids, endocrine disruption and on stem cells. Dr. Taylor has published more than 400 articles in leading medical journals and currently serves as the American Society for Reproductive Medicine (ASRM) president.
Mary Furmato, CPM, Senior Director, Strategy & Planning, Neurology, Ophthalmology & Women’s Health, Labcorp Drug Development
Mary Furmato has over 30 years with Labcorp Drug Development, where she has developed a wide range of experience in managing and monitoring U.S. and global studies in both diagnostic and device studies within broad therapeutic areas including cardiovascular, infectious disease, general medicine, neuroscience, ophthalmology and women’s health. Her experience conducting women’s health Phase II-IV global studies includes endometriosis, contraception, obesity and osteoporosis. Ms. Furmato’s focus is on fostering strong client relationships, providing guidance and mentoring for members of the study team and specializing in coordination of strategy development for successful study delivery.
Who Should Attend?
- Chief Medical Officer
- Chief Executive Officer
- Senior Medical Director
- Medical Director
- Regulatory Affairs Staff
- Clinical Development Director
- Research and Development Director
- Clinical Outcome Assessment Specialist
- Operational Director
- Senior Operational Director
- Clinical Director
- Senior Clinical Director
- Research Director
- Project Director
- Project Manager
What You Will Learn
- The heterogeneous nature of endometriosis and the effects on trial eligibility
- Current and developing diagnostic approaches, such as laparoscopic diagnosis, imaging and biomarkers
- Outcome measures for proof-of-concept studies and Phase III trials
- Operational considerations to support patient-centric trial design
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about Labcorp at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.